Roche's gantenerumab flop leaves lecanemab out in front in Alzheimer's

Swiss pharma giant Roche (ROG: SIX) was trading nearly 4% lower early Monday afternoon.

This followed the company’s presentation of results from the GRADUATE I and II studies evaluating gantenerumab in mild cognitive impairment due to Alzheimer’s and mild Alzheimer’s dementia.

The studies of the IgG1 antibody, an investigational medicine that is subcutaneously administered and designed to target and bind to aggregated forms of beta-amyloid, did not meet their primary endpoint of slowing clinical decline, even if gantenerumab was well tolerated.